Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- Abou-Alfa, Ghassan K
- Sahai, Vaibhav
- Hollebecque, Antoine
- Vaccaro, Gina
- Melisi, Davide
- Al-Rajabi, Raed
- Paulson, Andrew S
- Borad, Mitesh J
- Gallinson, David
- Murphy, Adrian G
- Oh, Do-Youn
- Dotan, Efrat
- Catenacci, Daniel V
- Van Cutsem, Eric
- Ji, Tao
- Lihou, Christine F
- Zhen, Huiling
- Féliz, Luis
- Vogel, Arndt
DOIAbstract
Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements
Add to ORKG